Coaching and mentoring are important tools for the leaders of today to be able to foster the next generation of talent in the biopharma sector. While the routes into industry have not changed dramatically – most leaders hold a master’s degree and/or PhD – the expectations of rising leaders have altered and the industry itself has become more collaborative. 

Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.

Executives and analysts predict trends spanning M&A, leadership diversity, curative gene therapy commercialization, biosimilars strategy and more. Expect technology innovation to continue to drive investment and deal making in biopharma.

CAR-T therapies from Janssen, Celgene and others will get a lot of attention at the annual hematology meeting, including candidates with novel constructs and targets.